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Abstract
The present study was focused to develop an alternative adjuvant for hepatitis B vaccine (HBsAg) using PLGA or PLA polymer as an
adjuvant. The HBsAg was successfully encapsulated in PLGA/PLA polymeric microparticles by solvent evaporation technique.
Polyvinyl alcohol (PVA) was used as continuous phase to stabilize the PLGA / PLA polymeric microparticles. Burst effect is the
foremost problem is associated with polyester polymeric system. However, to avoid the burst effect, an additional cross linker either
glutaraldehyde or dextran was employed during microencapsulation process. The HBsAg encapsulated microparticles were evaluated
for vaccine content, stability studies, in vitro release study and immunogenicity study. The morphology of HBsAg encapsulated PLGA
/ PLA microparticles were smooth and spherical in shape. The vaccine loading and release pattern of HBsAg from polymeric
microparticulate system were varied with polymer and cross linker concentrations. In this study, the antigen release was also influenced
by the type of polymer and cross linker used. Significant enhancement of antibodies was produced to HBsAg encapsulated PLGA and
PLA polymeric microparticles. Among two cross linker screened, dextran was found to be a better cross linker when compared to
glutaraldehyde because dextran cross-linked microspheres were smaller in size and more stable. Therefore, dextran cross-linked
microparticles were preferred for immunogenicity study. The results indicating that the PLGA and PLA polymeric system is an efficient
adjuvant for hepatitis B vaccine and found to be more compatible to elicit long lasting immune response.
© 2009 Elsevier B.V.
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1. Introduction
Vaccines are considered as the most successful medical interventions against infectious disease [1]. In spite of great success with
vaccines against infectious diseases such as small pox, polio, tetanus, diphtheria, hepatitis B and several others [2] facing many
obstacles because of logistical difficulty to attain immunization coverage with existing vaccines in certain part of the world,
especially in developing countries, these disease are still leading killers. Moreover, many significant obstacles remain, such as
improving sub optimal vaccines, developing new ones against diseases for which no vaccines yet exist and responding rapidly to new
emerging pathogens [3]. In designing an effective vaccine against particular pathogen involves certain key factors to target and trigger
the immune response [4]. Thus inclusion of immunopotentiators i.e. adjuvants to trigger early innate immune responses to aid in the
generation of robust and long lasting adaptive immune response is therapeutically very important. Therefore, traditionally, adjuvants
have been used in the vaccine formulation to improve vaccine efficacy [5, 6]. During the last 70 years, many adjuvant formulations
have been developed and a few of these have been evaluated in clinical trials. However, most of these were not accepted for routine
vaccines, mainly due to their toxicity and side effects. Aluminum compounds are still the only adjuvants approved by US FDA for
human use. Aluminum compounds used as vaccine adjuvants include aluminum hydroxide and aluminum phosphate. This may be
due to higher adsorption capacity at neutral pH. Conventional alum type vaccines require multiple recall injection at approximate
time intervals in order to achieve long lasting and optimal immune responses. However, it is very difficult to maintain especially in
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developing countries. Therefore, development of more efficient and safe adjuvant requiring single administration to obtain and long
lasting is of primary importance. In recent years great effort have been made to improve the efficacy of vaccination by using novel
adjuvants or antigen delivery systems. Controlled release of antigens from polymer microparticles has been of particular interest to
those interested in the development of vaccines, which would be effective in a single contact immunization [7]. In contrast to
aluminum salts polymeric controlled release systems may be deigned to release entrapped antigens for long time’s i.e weeks to
months after a single administration of vaccine and therefore by booster dose can be avoided. Moreover, polymeric microspheres are
capable of protecting antigens from rapid destruction in vivo, allowing for presentation of antigens in its native form to the cells of
immune system. Several recent studies have demonstrated the possible benefits of single dose vaccines in developed countries [8-11].
Continuous release of antigens from polymeric microspheres mimics the prime and boosting effect of immunization.
The decision to introduce a vaccine in to Expanded Programme on Immunization is influenced by a number of factors such as
disease burden, epidemiological aspects with special reference to transmission, vaccine factors that include safety, efficacy,
availability, feasibility of introduction, financial implications and projected or expected benefits in terms of morbidity, mortality and
cost effectiveness. Thus a vaccine that is ideal for introduction in to Expanded Programme on Immunization would be one that is
highly efficacious, economical, safe and protects against disease. Hepatitis B vaccine has been available for over 20 years. World
Health Organization has recommended that hepatitis B vaccination should be included immunization for all children world wide.
Accordingly, hepatitis B vaccine has been included in the national immunization programme of more than 130 countries [12, 13]. As
a result, various immunization strategies have been developed for routine infant vaccination, prevention of perinatal transmission and
catch up vaccination for old age groups. Currently available hepatitis B vaccines are immunogenic, efficacious and safe. But the
immune response varies with individual and declines with increasing age. Yet there is justification for producing more immunogenic
vaccines that could eventually be more efficacious in defined groups such as non responders to yeast derived vaccines or travelers and
health care workers who need rapid protection even after a priming dose of vaccine. The main target groups for such a vaccine should
consist of genetically, overweight and age associated non responders to conventional immunization, immunosuppressed and dialysis
patients as well as patients with chronic liver disease. A more immunogenic vaccine may also enable a reduction in the number of
injections in order to combat the social and cultural resistance to the use of syringes for long term protection against hepatitis B virus
infection. Prevention of diseases through immunization programme is the most cost effective heath arbitration. The World Health
Organization aims to develop more economical and effective vaccine against various diseases. Accordingly, the development of new
vaccines both more efficacious and easier deliver, has become a prime area of research work that can certainly benefit from recent
technical developments. The conversion of multiple dose vaccine in to single dose vaccine may represent an important advancement
to overcome the dropout rates due to cultural ethics against the use of syringes and economical crisis of people especially in under
developed countries. Taking this consideration in to account the ultimate goal of this research work is to develop a single contact
hepatitis B vaccine that can be administered soon after birth will be the greatest development towards the betterment of human health
care.
2. Methods
2.1. Materials
Poly (D, L) – lactide – co –glycolic acid (PLGA) with a lactide / glycolide (L/G) ratio of 50/50 (Mw 50 KDA, inherent viscosity
0.67 dl/g, polyvinyl alcohol (PVA, 87 – 89 % hydrolysed) and dicloromethane were purchased from Sigma Aldrich, USA.
Recombinant hepatitis B surface antigen (alum free) and alum adsorbed hepatitis B vaccine were obtained as a free sample from
Serum Institute of India, Pune. All other chemicals were of analytical grade. The immune response studies were carried out in healthy
Wistar rats and the animals were maintained and handled according to the standard guidelines.
2.2. Preparation of microspheres
1, 2 and 3 %( w/v) of PLGA and PLA polymeric solutions were prepared by dissolving in 1 ml of methylene chloride individually.
The polymeric solution was kept in a cylomixer for about 30 minutes and 2 ml (3mg /ml) of alum free hepatitis B vaccine was added
to form an emulsion. The emulsion so formed was sonicated for 20 seconds and dispersed individually in a magnetic stirrer for 10
minutes in 1 ml of 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 % v/v or w/v of glutaraldehyde or dextran respectively to stabilize the microspheres.
The system was maintained under magnetic agitation for 30 minutes. The resulting emulsion was dripped in to 400 ml of 3% poly
vinyl alcohol (PVA) solution. The system was maintained under magnetic stirrer for 8 hours to allow the solvent for evaporation. The
microspheres were collected after centrifugation at 10, 000 × g for 20 minutes. Microspheres were suspended in 10 ml of distilled
water and filtered through a membrane filter and dried in a vacuum desicator. The hepatitis B vaccine encapsulated PLGA
microspheres thus obtained were pooled and stored in a refrigerator.
2.3. Particle size and morphological features
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The average diameter of HBsAg encapsulated microspheres was measured by optical microscope (Olympus BX 50, Japan) in
which stage micro meter was employed. A minute quantity of microspheres was spread on the glass slide and the size of 100
microspheres was determined in each batch. The surface morphology was investigated using Scanning Electron Microscope (SEM).
Samples for SEM were mounted onto metal stubs and coated with gold palladium alloy to a thickness of 200-300 Ao. The mean
particle size was measured after performing the experiment in triplicate.
2.4. Determination of vaccine entrapment
50 mg of vaccine encapsulated micropsheres were suspended in phosphate buffer saline (pH 7.3) under shaking at room
temperature and kept for 3 hours. The suspension was centrifuged at 3000 × g for 30 minutes. After centrifugation the total protein
was determined by Lowry’s method and compared with standard curve data obtaining by assaying known concentration of vaccine.
The antigenically active HBsAg was determined by enzyme immunoassay using Immunlite 2000 automated analyzer (Diagnostic
products corporation, CA). The encapsulation efficiency was calculated from the percentage of encapsulated vaccine with respect to the
total amount of vaccine employed for preparation of microspheres.
2.5. Compatibility studies using Infra red spectrum
The interaction between vaccine and polymer was established by FTIR spectroscopy. Perkin Elmer spectrum one FT IR
instrument was used whose resolution was 1.0 cm-1. Conventional KBR pellet method was utilized in which 50 mg of sample and
150 mg of potassium bromide was taken in a mortar and triturated. The triturated sample was taken in to a pellet marker and was
compressed at 10 kg/cm2 using hydraulic press. The pellet was kept on to a sample holder and scanned from 4000 cm-1to 450cm-1. The
FTIR spectrum of HBsAg was performed by Neat method. In this method the vaccine sample was spread on the surface of sodium
chloride salt plate and was covered with another plate. The sample taken was adjusted by rotating and pressing the plate together to
squeeze out the excess material. Then the same was scanned from 4000 cm-1to 450cm-1.
2.6. Water uptake of microspheres
100 mg of microspheres was suspended in 20 ml of PBS (pH 7.4) containing 0.05% of tween 80 at room temperature for 24 hours
to measure water uptake. Microspheres were filtered, collected, weighed immediately (W1) and dried. After drying the microspheres
were weighed (W2). The percentage water uptake (W) of microspheres was calculated by applying the following formula W= (W1 -
W2)/ W2×100.
2.7. Stability studies
2.8. The stability of formulated HBsAg encapsulated microspheres was determined over a period of 8 weeks. The vaccine loaded
microspheres exposed at 40 C, room temperature and at 500 C. After 15, 30 and 60 days the size and vaccine content of microspheres
were determined. The vaccine content was determined using Immunlite 2000 HBsAg automated assay kit (Diagnostica product
corporation, CA).
2.9. In vitro release profile
100 mg of HBsAg encapsulated microspheres were suspended in 50 ml of phosphate buffer saline of pH 7.4 containing 0.2
% of tween 80 and 0.1% of sodium azide in a conical flask and incubated at 370C by keeping the flask in a shaker cum incubator. At
predetermined time intervals that is every seventh day up to 105th day. 2 ml of vaccine releasing solution was removed and fresh
medium was replaced. The samples were centrifuged at 4000 × g for 15 minutes and the supernatant solution was analyzed by enzyme
immune assay using Immulite 2000 HBsAg assay kit (Diagnostica product corporation, CA).
2.10. Immunogenicity studies
The immunogenicity studies were carried out by antibody induction method. 30 healthy Wistar rats (150 – 250 gms) were selected
for the study and they were divided in to 5 groups. Each group containing 6 Wistar rats and housed in a separate microlon boxes
(Torson products, Kolkata) for the purpose of acclimatization. The size of the animal box is 45 × 27 × 15 cm. They had free access to
water and standard pellet diet through out the study. The immune response was determined by measuring specific antibodies and
immunoglobulin levels. All the animals were received 0.5 ml of vaccine having 2 µg (1/10th of standard human dose) injected intra
muscularly and some of the groups received booster dose 4 weeks after primary immunization. The various treatment groups are
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Group 1 - Immunized with a single dose of hepatitis B vaccine encapsulated PLGA microspheres.
Group 2 - Immunized with a single dose of hepatitis B vaccine encapsulated PLA microspheres.
Group 3 - Immunized with a single dose of alum adsorbed hepatitis B vaccine
Dosage and immunization protocol
Vaccine dose (per inoculum) - 0.5 ml containing 1/ 10th of SHD (2 mcg)
Route of inoculation - intra muscular
Primary immunization - on the “0 day”
Booster dose (wherever applicable) - 4 weeks after primary immunization
Bleeding time - 45th day & 90th day
The quantitative measurement of anti HBs was determined using Immulite 2000 automated analyzer (Diagnostic products
corporation, CA) and the IgG and IgM were determined by Turbox IgG, IgA and IgM assay (Orion Diagnostica). The IgE level was
analyzed by Immulite 2000 IgE analyzer.
3. Results
The PLGA and PLA microspheres were successfully prepared by solvent evaporation technique. In both PLGA and PLA
polymeric system the size of the microspheres was directly proportional to the concentrations of cross linking agent as well as
polymer concentration. In our experimental work 2% w/v either PLGA or PLA with 2 % v/v of glutaraldehyde or 2 % w/v of dextran
were found to be ideal to formulate stable microspheres. The microparticles were smooth, discrete particles having small pore on it
surfaces. The HBsAg encapsulated glutaraldehyde cross linked PLGA and PLA microspheres showed a characteristics peak at various
frequencies. The FTIR spectrum of HbsAg, PLGA, PLA polymers, HBsAg encapsulated PLGA/PLA microspheres are presnted in
table 1.
Table 1
FTIR Spectrum of hepatitis B vaccine, PLGA, PLA polymers and their microspheres with hepatitis B vaccine
Characters Frequency cm-1 Groups
Hepatitis B vaccine 3436, 2919, 2850, 1657 & 1021 N-H(ST), C-H (ST), C-H (ST), C=C (ST),
C-N (ST), C-C (ST)
PLGA polymer 2919, 2850, 2320, 1655, 1463
&1100
C-H(ST), C=C(ST), C-H (B), C=N(ST),
C-O-C (ST)
PLA polymer 2998, 2947, 1756, 1437, 1384, 1187
& 1088
C-H (ST), O-H (ST), C=O(ST), CH3 - CH3,
C-N(ST), C-N (ST)
Vaccine encapsulated
PLGA*
Microspheres
3444, 2924, 2853, 1748, 1630, 1459
& 1081
N-H (ST), C-H (ST), C-H (S-T), C=O
(ST), N-H (B), C-H (B), C-N (S-T)
Vaccine encapsulated
PLGA**
Microspheres
3436, 2924, 2853, 1751, 1631
&1091
N-H (ST), C-H (ST), C-H (S-T), C=O
(ST), N-H (B), C-N (S-T)
Vaccine encapsulated
PLA* Microspheres
3436, 2924, 1748, 1653, 1459, 1187,
1083 &747
N-H (ST), C-H (ST), C=O (ST), C=C
(ST), C-H (B) , C- N (ST), C-N(ST), C-Cl
(ST)
Vaccine encapsulated
PLA** Microspheres
3468, 2998, 2947, 1751, 1629, 1457,
1387, 1086, 865 and 750.
OH (ST), C-H (ST), C-H (ST), C=O (ST),
N-H (B), C-H (B), CH3-CH3,C-N (ST), C-
O-O-C (ST), C-Cl (ST)
* glutaraldehyde cross linkerd, ** dextran cross linked
ST – streching vibrations and B – bending vibrations
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The water uptake properties of glutaraldehyde or dextran cross linked PLGA and PLA microspheres are more or less same. The
weight and size of microspheres were increased even after drying. The absorption of water was found to be more or less same in both
glutaraldehyde and dextran cross linked PLGA and PLA microspheres. The loading of vaccine was found to be around 38 – 45 % in
both PLGA and PlA microspheres. The loading capacity varied with polymer and cross linker concentrations and type of cross linker
used. The stability studies was ascertained by observing the size and percentage of vacciine loading in polymeric microspheres. The
table 2 reveals that the stability studies of hepatitis B vaccine encapsulated microspheres at various temperature over a period of 8
weeks.
Table 2
The stability studies of hepatitis B vaccine loaded and unloaded microspheres atvarious temperatures
over a period of 8 weeks
NS -No Shape, x- P< 0.01 (Extremely significant), z - P< 0.05 (Significant), *Glutaraldehyde as cross linker,
** Dextran as cross linker, RT-Room temperature
Size (µm) Percentage of loadingFormulation Weeks
40C RT 500C 40C RT 500C
0 27.8 ± 0.2x 27.8 ± 0.2x 27.8 ± 0.2x - - -PLGA*
8 27.8 ± 0.2z 22.7 ± 0.6x NS - - -
0 35.02 ± 0.9x 35.02 ± 0.9x 35.02± 0.9x 42.16 ± 0.4x 42.16 ± 0.4x 42.16 ± 0.4xPLGA*
8 35.02 ± 0.9x 25.4 ± 0.9x NS 42.1 ± 0.4x 38.16 ± 1.4z 18 ± 1.2
0 24.8 ± 0.2x 24.8 ± 0.2x 24.8 ± 0.2x - - -PLGA**
8 24.8 ± 0.2x 25.2 ± 0.3x NS - - -
0 34.06 ± 0.9x 34.03 ± 1.9x 35.1± 0.9x 40 ± 1.2 40 ± 1.2 40 ± 1.2PLGA**
8 34.06 ± 0.9z 34.86 ± 2.9x NS 39.7 ± 1.4z 39.6 ± 1.7 26.8 ± 1.2
0 26.1 ± 0.3x 26.1 ± 0.3x 26.1 ± 0.3x - - -PLA*
8 25.7 ± 1.3x 26.1 ± 0.1x NS - - -
0 38.09 ± 2z 38.09 ± 2x 38.89 ± 2x 41 ± 1.4 41 ± 1.4 41 ± 1.4PLA*
8 37.89 ± 1.7x 31.09 ± 1.4x NS 40.8 ± 1.3 31.2 ± 1.3 10.1 ± 0.6
0 27.2 ± 0.6x 27.2 ± 0.6x 27.2 ± 0.6x - - -PLA**
8 26.9 ± 0.9x 27.1 ± 0.9x NS - - -
0 23.6 ± 0.3 23.6 ± 0.3 23.6 ± 1.3 35.8 ± 2z 35.8 ± 2 36.8 ± 2.2PLA**
8 23.6 ± 0.3Z 22.9 ± 1.3 NS 34.8 ±
1.9 z
34.3 ±1.2z 19.8 ± 0.6
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The release pattern of HBsAg from PLGA & PLA microspheres were studied for 105 days (15 weeks). The fig 1 depicit the invitro
release pattern of HBsAg from PLGA and PLA microspheres. In the case of glutaraldehyde cross linked microspheres, the significant
peak antigen release (p < 0.005) was observed up to 70th day and almost 42 % release was observed during this period. However, the
release was maintained up to 84th day i.e 12 weeks and the observation made after 84th day showed loss of antigen and no release could
be detected in the releasing medium.
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Fig 1. In vitro release profile of HBsAg from PLGA/PLA microspheres
On the other hand, significant peak antigen release (p< 0.005) could be observed on 77th day from dextran cross linked PLGA
microspheres and maintained up to 91 days i.e 13 weeks and the observation made after 91st day showed loss of antigen and no release
could be detected in the releasing medium. In the case of glutaraldehyde cross linked PLA microspheres, the significant peak antigen
release (p < 0.005) was observed on 63rd day almost 52 - 55 % of antigen was released from the microparticles. However, the release
was maintained up to 84 days i.e 12 weeks and the observation made after 84th day showed that no release could be detected in the
releasing medium. However, dextran crosslinked PLA microspheres released antigen of about 25% in first seven days. Significant
peak antigen release (p < 0.005) was observed on 63rd day almost 54 - 56 % of antigen was released from the microparticles. However,
the release was maintained up to 84 days i.e 12 weeks and the observation made after 84th day showed that no release could be detected
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in the releasing medium. With respect to antigen release in vitro, the In vivo results also confirmed the release of antigen. Significant
antibodies was produced up to 90th day against HBsAg encapsulated PLGA and PLA microparticles (Table 3).
Table 3
A comparative immunogenicity study
Anti HBs (IU / L) IgG (mg / dl) IgA ((mg / dl) Ig M (mg / dl)Group
45th 90th 45th 90th 45th 90th 45th 90th
Group 1 10.2 ± .6 11.3 ± 0.3 793.6 ±
2.4
791.3 ±
1.3
77.8 ± 2.3 78.8 ±
2.6
85 ± 1.2 85.3 ±
1.8
Group 2 10.1 ± 0.2 11.2 ± 0.1 793± 1.7
789.6 ±
2.3
75.1 ± 1.7 77.3 ±
2.1
80 ± 1.6 85.3 ±
1.4
Group 3 10.1± 0.6 10.9 ± 1.3
793.6 ±
1.7
789.6 ±
2.3
75.1 ± 1.7 77.3 ±
2.1
80 ± 1.6 85.3 ±
1.4
Group 1 animals received hepatitis B vaccine encapsulated PLGA microspheres. Group 2 animals received hepatitis B vaccine
encapsulated PLA microspheres. Group 3 animals received conventional alum adsorbed hepatitis B vaccine. Each value is a mean of 6
batches with a standard deviation and all the values are extremely significant (p  0.001) Dunnet multiple comparison test.
Discussion
Burst effect is the basic obstacle in vaccine polyester microparticulate system has been modified by employing a cross linker either
glutaraldehyde or dextran. Generally the size of microparticles dicdates the immune response. The larger microspheres show the
slower release of vaccine and prolongs the immunogenicity effect [14]. The PLGA and PLA microspheres were smooth, spherical in
shape and contains minute pores on the surfaces. The proportion of vaccine loading in both PLGA and PLA microspheres were 40 –
43 % and 35- 43 respectively and rest of the vaccine was lost during microencapsulation process. During the cross linking and
hardening process the vaccine could be lost either due to stirring process or chemical interaction. Previously it has been reported [15]
that drug loss during a microencapulation process using a double emulsion technique occured because of the migration of inner water
droplets to the external aqueous phase. the maximum loading of vaccine in to the PLGA polymeric system was attained, when 2 %
w/v of PLGA cross linked with 2 % v/v of glutaraldehyde was used. However, in the case of dextran cross linked PLGA microspheres
the maximum vaccine entrapment was achieved at 2 % w/v of PLGA cross linked with 2 % w/v of dextran. In the case of PLA
polymeric system, The maximum vaccine entrapment could be detected when 2 % w/v of PLA polymer cross linked with 2 % v/v of
glutaraldehyde or 2 % w/v of dextran. The final appearance of infra red spectrum is very important in the interpretation process. The
FT IR spectrum is an efficient tool to monitor the presence of chemical groups. In this study, the IR spectrum of hepatitis B vaccine
has displayed broad band at 3436 cm-1, which indicated the stretching band of heterocyclic amine and a sharp band at 2919 cm-1
indicates the asymmetrical stretching vibrations of methylene group. Bands at 1657 and 1021 cm-1 proved the presence of alkenyl and
primary amine groups with stretching vibrations. Moreover, few very short bands were also observed at 2850 and 1261 cm-1, which
proved the presence of methylene group stretching vibrations and primary or secondary OH group in bending vibration. The FT IR
spectrum of PLGA polymer showed the characteristic peak at 3401 cm-1 indicated the presence of aromatic amine (N-H) stretching
vibration. The sharp band at 2919 cm-1 is the characteristic peak of methylene group (C-H) asymmetric stretching and the sharp band at
2850 cm-1 is the characteristic peak of methylene group (C-H) symmetrical stretching. The peaks at 1655 and 1463 cm-1 proved the
presence of open chain immuno group (C=N) stretching and alkane (C-H) bending vibration. The hepatitis B encapsulated
glutaraldehyde cross linked PLGA microspheres showed a characteristic peaks at various frequencies. The wide band at 3444 cm-1
indicates the presence of heterocyclic amine group with stretching vibration. But the frequencies obtained in hepatitis B vaccine
before microencapsulation was 3436 cm-1. This indicates that there is some interaction between either with polymer or with
glutaraldehyde, which led to a shift from 3436 to 3444 cm-1. The band at 2924 cm-1 proved the presence of methylene group with
asymmetrical stretching. However, asymmetrical stretching with methylene group could be found at 2919 cm-1 before encapsulation
of hepatitis B vaccine. The short band at 1081 cm-1 is a characteristic peak of primary amine with stretching vibrations. However,
similar type of bands could be observed at 1021 cm-1 before encapsulation of hepatitis B vaccine. The comparative study with bands
of glutaraldehyde cross linked PLGA microspheres without encapsulation of hepatitis B vaccine did not produce any characteristis
peaks as like HBsAg encapsulated PLGA microspheres. But some peaks were short displayed at 2946 and 2995 cm-1 proved the
presence of methylene group with asymmetrical stretching. Similar type of band could be observed at 2919 and 2850 cm-1 of PLGA
polymer. From the comparative results, it is understood that significant absorption shift was detected after the formation of
microspheres. This might be due to the interaction between PLGA polymer and glutarldehyde. Therefore, these bands at various wave
cycles at cm-1 proved the encapsulation of hepatitis B vaccine in PLGA microspheres using glutaraldehyde as cross linker. Sunil
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Agnihotri et al (2006) investigated novel interpenetrationg network chitosan – poly (ethylene oxide - δ- acrylamide) hydrogel
microspheres for the controlled release of capecitabine. In their study the grafting, interpenetrating network formation and chemical
stabilaity of the capecitabine after encapsulation in to microspheres was confirmed by FTIR analysis. The spectral data confirmed the
presence of chracterstics band at 2888 and 1464 cm-1 indicate the presence of CH2 group with stretching and bending vibrations
respectively. The bands at 1412 cm-1 indicate the presence of CH2 group with stretching and bending vibrations respectively. The
bands at 1412 cm-1 indicate the C-H bending vibrations, while the bands at 1097 cm-1 confirm the presence of ethereal C-O stretching.
The hepatitis B vaccine encapsulated, dextran cross linked PLGA microspheres displayed characteristic peaks at 3436, 2924 and 2853
cm-1 and indicated the presence of heterocyclic amine stretching vibration, asymmetrical and symmetrical stretching of methylene
group. The presence of peak at 3436 cm-1, a shift from 2919 to 2924 and 2850 to 2853 cm-1 indicated the presence of hepatitis B
vaccine in dextran cross linked PLGA microspheres. Peaks at 1751, 1631 and 1091 cm-1 indicated the presence of alkyl carbonate
(C=O) stretching, (N-H) primary amine bending and (C-N) primary amine. The comparative study with bands of dextran cross linked
PLGA microspheres without encapsulation of hepatitis B vaccine did not produce any characteristis peaks as like HBsAg
encapsulated PLGA microspheres. Therefore, these bands at various wave cycles at cm-1 proved the encapsulation of hepatitis B
vaccine in PLGA microspheres using glutaraldehyde as cross linker.
The FT IR spectrum of PLA polymer displayed characteristic peak at 3503 cm-1 specified the presence of aromatic amine (NH)
stretching, 2998 & 2947 cm-1 aliphatic stretching (C-H), 1756 cm-1 alkyl carbonate (C=O) stretching, 1457 cm-1 (C-H) methyl group
bending, 1384 cm-1 di methyl (iso) group, 1187 cm-1 (C-N) secondary amines stretching, 1088 cm-1 (C-N) primary amine stretching.
The hepatitis B vaccine encapsulated PLA polymeric system with glutaraldehyde as cross linker revealed characteristic peak at 3436
cm-1 specified the presence of heterocyclic amine stretching. Similar type of band could be observed for hepatitis B vaccine before
microencapsulation process. The band at 1748 cm-1 showed the presence of alkyl carbonate group stretching vibration. Similar type of
band could be observed in PLA polymer at 1756 cm-1 and 1755 cm-1 in the case of PLA microspheres with out vaccine. Moreover, the
bands at 1653, 1459, 1187 and 1083 cm-1 indicated the presence of alkenyl stretching (C=C), methyl asymmetrical stretching,
secondary amine (C-N) stretching and primary amine stretching respectively. The glutaraldehyde cross linked PLA microspheres
without vaccine showed a wide band at 3445 cm-1, which indicated the presence of heterocyclic amine stretching. But after
encapsulation of hepatitis B vaccine similar type of band could be observed at 3436 cm-1, which was similar as in FT IR spectrum of
hepatitis B vaccine. This proved the encapsulation of hepatitis B vaccine in the glutaraldehyde cross linked PLA microspheres.
Moreover, all the other bands were the indicative of chemical shifts due to microencapsulation. In the case of dextran cross linked,
hepatitis B vaccine encapsulated PLA microspheres depicted various characteristic peaks at 3468 cm-1 and indicated the presence OH
group stretching vibration, which was an indicative of chemical interaction either with polymer or with dextran during
microencapsulation. All other groups were similar with slight chemical shift occurred at 1751, 1457, 1387 and 1086 cm-1, when
compared with dextran cross linked PLA microspheres with out vaccine.
The water uptake of microspheres is an important parameter to find out the burst effect. In PLGA polymeric system, the weight of
glutaraldehyde cross linked PLGA microspheres increased around 23 mg with an increase in size of 2 µm and the weight of dextran
cross linked PLGA microspheres was increased around 24 mg with an increased in size of 3 µm. In the case of PLA polymeric system,
the weight of glutaraldehyde cross linked PLA microspheres increased to 20 mg with an increased in size of about 1 µm. and the
weight of dextran cross linked PLA microspheres increased to 22 mg with an increase in size of 2 µm. On the other hand, the weight of
glutaraldehyde cross linked chitosan microspheres was increased to 22 mg with an increased in size of 4 µm and the weight of dextran
cross linked chitosan microspheres was increased to 25 mg with an increased in size of about 6 µm. Generally, it is very clear that the
water absorption is less when glutaraldehyde was used as cross linking agent rather than dextran as cross linking agent.
Conventionally poly vinyl alcohol has been used as stabilizing agent for preparing poly ester polymers PLGA and PLA
microspheres. However, in this research work an additional cross linker either glutaraldehyde or dextran was employed inorder to
stabilize more and to avoid burst effect. Maria Alonso et al, (1999) investigated high water absorption of PLGA microspheres with
various stabilizers like dextran, heparin and trehalose. On the other hand, 18 – 22 % of water absorption of chitosan microspheres
could be observed either with glutaraldehyde or dextran as cross linker in this study. Kwunchit Oungbho and Muller (1997) found
that the uptake of water in both N- acetylchitosan and cross linked chitosan sponges was more than 20 times of their weight. Anthony
Amachei Attama et al, (2007) observed 2 to 5 times of water absorption in mucuna gum microspheres with glutaraldehyde as cross
linker. In our study we could not observed burst effect on 1st day which showed on in vitro release profile. Matsumoto et al, (2005)
reported that the PLGA microspheres with the inner drug holding layer of gelatin showed rapid water uptake, which led to destruction
of the outer layer occurred at the early period and caused initial burst as observed in the study. They investigated that the PLGA
showed a higher water uptake than PLA.
The stability studies were demonstrated by the size of microspheres and percentage vaccine loading in polymeric
microspheres were carried out in hepatitis B vaccine loaded and unloaded microspheres at various temperatures over a period of 8
weeks. In PLGA polymeric system, the glutaraldehyde cross linked PLGA microspheres with either vaccine loaded or vaccine
unloaded were stable at 4oC. The size and percentage vaccine loading were not changed at 4oC. However, the size was reduced after 8
weeks of storage. The size and percentage loading of vaccine did not alter even after 8 weeks of storage. Therefore, the glutaraldehyde
cross linked vaccine loaded and unloaded microspheres were stable at 4oC for about 8 weeks of storage. However, the size of vaccine
loaded and unloaded microspheres were reduced at room temperature and no shape could be observed at 50oC. Therefore, the
microspheres were totally disintegrated and the size of microspheres was unable to measure. On the other hand, reduced percentage
loading could be observed after 8 weeks of storage at room temperature and 50oC. The percentage of vaccine loading was extremely
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significant at 4oC, significant at room temperature and non significant at 50oC (Table 2 ). In the case of dextran as cross linker, the
vaccine loaded and unloaded microspheres were stable at 4oC and room temperature. The percentage of loading in PLGA
microspheres was also not affected even after storage at room temperature for 8 weeks. Moreover, disintegration of microspheres at
50oC led to non shape of PLGA microspheres and the percentage of vaccine loading was also drastically decreased. The significant
percentage vaccine loading could be observed at 4oC and non significant percentage of vaccine loading could be observed at room
temperature and 50oC after 8 weeks of storage (Table 2). In the case of glutaraldehyde or dextran cross linked PLGA microspheres
drastic loss of vaccine could be observed at 50oC. Therefore, at 50oC the microspheres were disintegrated and the nature of vaccine also
destroyed. This might be due to the glass transition temperature (Tg) of PLGA polymer. The Tg of PLGA polymer is 40 – 60oC,
which was not modified either with glutaraldehyde or with dextran as cross linker while preparing microspheres. Similar type of
result was observed earlier by Xinagguo Mei et al, (2006) PLGA microspheres as sustained release carrier for leutinizing hormone.
They investigated that PLGA 75 / 25 polymer had a Tg value of 38oC, whereas drug loaded microspheres exhibited considerably
higher Tg values of 42oC. In the present work there could be increased in Tg value after encapsulation of vaccine in PLGA
microspheres but it also led to particle degradation.
In the case of PLA polymeric system, the glutaraldehyde cross linked PLA microspheres either with vaccine loaded or
vaccine unloaded microspheres were stable at 4oC. The size of glutaraldehyde PLA microspheres did not change at 4oC and at room
temperature after 8 weeks of storage. However, the size of vaccine loaded microspheres was not changed at 4oC but the size was
reduced at room temperature. This reflects in vaccine loading also, which was not changed at 4oC and decreased at room temperature
after 8 weeks of storage. In the case of dextran cross linked PLA microspheres the size of PLA microsphres was not changed at 4oC and
at room temperature even after 8 weeks of storage. With respect to particle size the vaccine loading also not changed at 4oC and room
temperature after 8 weeks of storage. In the case of glutaraldehyde or dextran cross linked PLA microspheres drastic loss of vaccine
could be observed at 50oC, followed by the disintegration of microspheres, resulting in the destruction of the nature of vaccine. This
might be due to the glass transition temperature (Tg) of PLA polymer. The Tg of PLA polymer was indicated as 50 – 80oC, which was
not modified either with glutaraldehyde or with dextran as cross linker while preparing microspheres. The table 3 representing a
comparative immunoglobulin titre on 45th and 90th day after a single step immunization with HBsAg encapsulated PLGA/PLA
microspheres. The required amount of anti HBs level for protein is 10 IU/L after vaccination. In this study interestingly significant
anti HBs level was observed even up to 90th day after single shot injection. The conventional alum adsorbed vaccines induced
minimum protection level but antibodies levels were quite less especially specific antibody level when compared to HBsAg
encapsulated PLGA or PLA microspheres. Moreover, no significant release of IgE could not able to detect and proved that the vaccine
formulation did not produce any allergic reaction. Thus the total immunological system was boosted up to induce good immune
response.
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